B
Bull
Bull · 25%ATHA
$0.44
シナリオ価格
$6.750
-0.413 (-6.12%)終値時点
Loading chart…
- High
- 7.350
- Open
- 7.300
- VWAP
- 6.91
- Vol
- 70.31K
- Mkt Cap
- 101.19M
- Low
- 6.620
- Amount
- 485.63K
- EV/EBITDA, TTM
- 0.00
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations.
バリュエーション指標
The current forward P/E ratio for LeonaBio Inc (ATHA) is -1.30, compared to its 5-year average forward P/E of -1.40.
Alphio AI Price Scenarios for ATHA
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
8.505-15Yahoo FinanceAthena Gold Provides Exploration Update on Laird Lake Project
6.002-19CNBCLatest Rating Changes on Wall Street
1.001-19Yahoo FinanceAthena Gold Invites Investors to Vancouver Resource Investment Conference
3.501-09GlobenewswireAthira Pharma Rebrands to LeonaBio, Secures $90 Million Financing
9.012-20NASDAQ.COMWeekly Update: CYTK Receives Initial FDA Approval, INSM Concludes Rhinosinusitis Research, XOMA Purchases GBIO
ATHA FAQ — answered by Alphio AI
LeonaBio, Inc., formerly Athira Pharma, Inc., is a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The Company's lead drug candidates, lasofoxifene and ATH-1105, are novel, small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. ATH-1105 is a novel, orally available, brain-penetrant, next-generation small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for potential treatment of neurodegenerative diseases, including ALS, Alzheimer's disease, and Parkinson's disease. Lasofoxifene is a novel, nonsteroidal SERM with a binding profile, designed to confer potent activity against both wild-type and mutant estrogen receptors, including the clinically significant ESR1 mutations. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。